News and media

| 22/12/2016

Congratulations to this year’s successful applicants in the annual National Health and Medical Research Council (NHMRC) grant funding round. More than $4 million has been awarded for motor neurone disease (MND) research. 

| 22/12/2016

Applicants must be an Australian citizen or have permanent resident status. Applications close at 6 pm EST on Friday 27 January 2017.

| 13/12/2016

A phase II clinical trial led by Dr Michael Benatar from the University of Miami Miller School of Medicine has found a heat shock protein-based therapy shows potential for the treatment of ALS patients with mutations in the SOD1 gene.

| 12/12/2016

​It has been another extraordinary year for the Motor Neurone Disease Research Institute of Australia. Thirty-two grants worth $3.75 million have been awarded for research to start in 2017.

| 24/11/2016

Professor Bartlett has had a long and distinguished career in neuroscience research and many years serving as a member of the MND Research Institute of Australia Research Committee. 

| 22/11/2016

The Lighthouse Project is a clinical trial to test whether MND is caused or triggered by human endogenous retroviruses (HERVs). The trial is now recruiting participants in NSW and Victoria.
 

| 31/10/2016

 It's been another busy year for the MND Australia team with main accomplishments including "The Fading Symphony", launch of the Deloitte Access Economics report "Economic analysis of MND in Australia", development of the MND 'red flags' diagnostic tool for GPs and MND Research Institute of Australia funding of a record 42 new research grants in 2016.
 

| 28/10/2016

​The MNDRIA Research Committee has awarded 32 new grants to commence in 2017.

Two new grants have been awarded this year.

| 25/10/2016

Thanks to the wonderful support from donors, bequestors and the State MND Associations, at last week's Grants Allocation Meeting the MND Research Institute of Australia allocated $3.75 million for research commencing in 2017.
 

| 14/10/2016

When it comes to understanding clinical trials, accessible information can be hard to come by. 

The media are currently focusing on two important motor neurone disease (MND) clinical trials, the Lighthouse Project and Copper-ATSM. 

The team at MND Australia has developed a series of easy-to-understand explanations of the trials and what the expected outcomes might mean for future MND treatments.